激素冲击疗法、人免疫球蛋白冲击疗法联合血小板输注法治疗重症ITP的效果观察  

Effect observation of hormone pulse therapy, human immunoglobulin pulse therapy combined with platelet transfusion on severe ITP

作　　者：徐娜[1] XU Na(Shenyang Red Cross Hospital,Shenyang 110031,China)

机构地区：[1]沈阳市红十字会医院,110031

出　　处：《中国实用医药》2023年第1期139-141,共3页China Practical Medicine

摘　　要：目的观察激素冲击疗法、人免疫球蛋白冲击疗法联合血小板输注法治疗重症原发免疫性血小板减少症(ITP)的临床疗效。方法40例重症原发免疫性血小板减少症患者,随机分为对照组和观察组,各20例。对照组患者采用激素冲击疗法联合人免疫球蛋白冲击疗法治疗,观察组患者采用激素冲击疗法、人免疫球蛋白冲击疗法联合血小板输注法治疗。比较两组患者临床疗效、不良反应发生情况、血小板计数≥100×10^(9)/L的持续时间及治疗前后血小板计数。结果观察组治疗总有效率为90.0%(18/20),高于对照组的60.0%(12/20),差异具有统计学意义(P<0.05)。治疗前,两组血小板计数比较,差异无统计学意义(P>0.05);治疗后,观察组血小板计数(157.46±10.37)×10^(9)/L高于对照组的(132.15±5.13)×10^(9)/L,血小板计数≥100×10^(9)/L的持续时间(14.21±3.01)d长于对照组的(8.12±1.36)d,差异具有统计学意义(P<0.05)。观察组不良反应发生率为15.0%(3/20),对照组不良反应发生率为20.0%(4/20),比较差异无统计学意义(P>0.05)。结论采用激素冲击疗法、人免疫球蛋白冲击疗法联合血小板输注法治疗原发免疫性血小板减少症效果显著,可有效提升血小板计数,且不会增加不良反应,具有临床推广价值。Objective To observe the clinical efficacy of hormone pulse therapy, human immunoglobulin pulse therapy combined with platelet transfusion on severe primary immune thrombocytopenia(ITP). Methods A total of 40 patients with severe primary immune thrombocytopenia were randomly divided into control group and observation group, with 20 patients in each group. Patients in the control group were treated with hormone pulse therapy and human immunoglobulin pulse therapy, while patients in the observation group were treated with hormone pulse therapy, human immunoglobulin pulse therapy and platelet transfusion. Both groups were compared in terms of clinical efficacy, occurrence of adverse reactions, duration of platelet count ≥100×10^(9)/L and platelet count before and after treatment. Results The total effective rate of the observation group was 90.0%(18/20),which was higher than 60.0%(12/20) of the control group, and the difference was statistically significant(P<0.05).Before treatment, there was no statistically significant difference in platelet count between the two groups(P>0.05).After treatment, the platelet count in the observation group was(157.46±10.37)×10^(9)/L, which was higher than(132.15±5.13)×10^(9)/L in the control group;the duration of platelet count ≥ 100×10^(9)/L in the observation group was(14.21±3.01) d, which was longer than(8.12±1.36) d in the control group;the differences were statistically significant(P<0.05). The incidence of adverse reactions in the observation group was 15.0%(3/20), while that in the control group was 20.0%(4/20), and the difference was not statistically significant(P>0.05). Conclusion Combination of hormone pulse therapy, human immunoglobulin pulse therapy and platelet transfusion for the treatment of severe primary immune thrombocytopenia can effectively increase platelet count without increasing adverse reactions, which has the value of clinical promotion.

关 键 词：激素冲击疗法 人免疫球蛋白冲击疗法 血小板输注法 重症原发免疫性血小板减少症 

分 类 号：R558.2[医药卫生—血液循环系统疾病]